JP2015536943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536943A5 JP2015536943A5 JP2015540614A JP2015540614A JP2015536943A5 JP 2015536943 A5 JP2015536943 A5 JP 2015536943A5 JP 2015540614 A JP2015540614 A JP 2015540614A JP 2015540614 A JP2015540614 A JP 2015540614A JP 2015536943 A5 JP2015536943 A5 JP 2015536943A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- diabetes
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0124724 | 2012-11-06 | ||
| KR1020120124724A KR101993393B1 (ko) | 2012-11-06 | 2012-11-06 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PCT/KR2013/009990 WO2014073845A1 (en) | 2012-11-06 | 2013-11-06 | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018123263A Division JP6666959B2 (ja) | 2012-11-06 | 2018-06-28 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536943A JP2015536943A (ja) | 2015-12-24 |
| JP2015536943A5 true JP2015536943A5 (enExample) | 2016-12-28 |
| JP6363613B2 JP6363613B2 (ja) | 2018-07-25 |
Family
ID=50684885
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540614A Active JP6363613B2 (ja) | 2012-11-06 | 2013-11-06 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
| JP2018123263A Active JP6666959B2 (ja) | 2012-11-06 | 2018-06-28 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
| JP2020028080A Active JP7050834B2 (ja) | 2012-11-06 | 2020-02-21 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
| JP2022016603A Active JP7341263B2 (ja) | 2012-11-06 | 2022-02-04 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018123263A Active JP6666959B2 (ja) | 2012-11-06 | 2018-06-28 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
| JP2020028080A Active JP7050834B2 (ja) | 2012-11-06 | 2020-02-21 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
| JP2022016603A Active JP7341263B2 (ja) | 2012-11-06 | 2022-02-04 | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150299282A1 (enExample) |
| EP (2) | EP2916860B1 (enExample) |
| JP (4) | JP6363613B2 (enExample) |
| KR (1) | KR101993393B1 (enExample) |
| CN (1) | CN104918632B (enExample) |
| AR (2) | AR093386A1 (enExample) |
| AU (3) | AU2013342324B2 (enExample) |
| BR (3) | BR122021003984B1 (enExample) |
| CA (1) | CA2890329C (enExample) |
| CL (1) | CL2015001207A1 (enExample) |
| DK (1) | DK2916860T3 (enExample) |
| EA (2) | EA037956B1 (enExample) |
| ES (1) | ES2802099T3 (enExample) |
| HR (1) | HRP20200925T1 (enExample) |
| HU (1) | HUE049240T2 (enExample) |
| IL (2) | IL238631B (enExample) |
| LT (1) | LT2916860T (enExample) |
| MX (2) | MX360335B (enExample) |
| MY (1) | MY173828A (enExample) |
| NZ (2) | NZ738835A (enExample) |
| PE (1) | PE20151420A1 (enExample) |
| PH (2) | PH12015501009B1 (enExample) |
| PL (1) | PL2916860T3 (enExample) |
| PT (1) | PT2916860T (enExample) |
| SG (3) | SG11201503420QA (enExample) |
| TW (4) | TWI754980B (enExample) |
| UA (2) | UA117570C2 (enExample) |
| WO (1) | WO2014073845A1 (enExample) |
| ZA (1) | ZA201503999B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181591T1 (hr) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže |
| AU2012270366C1 (en) | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| NZ739063A (en) | 2012-11-06 | 2019-11-29 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| MY192248A (en) * | 2014-03-31 | 2022-08-10 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| TN2017000271A1 (en) * | 2014-12-30 | 2018-10-19 | Hanmi Pharm Ind Co Ltd | Glucagon derivative having improved stability |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TN2017000555A1 (en) * | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| EP3355931B1 (en) | 2015-10-01 | 2024-06-26 | Novo Nordisk A/S | Protein conjugates |
| EP3359191A4 (en) * | 2015-10-05 | 2019-05-29 | Merck Sharp & Dohme Corp. | ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1 |
| WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| PH12018501409B1 (en) | 2015-12-31 | 2023-03-10 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| KR101887576B1 (ko) * | 2016-04-15 | 2018-08-13 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| JP7208020B2 (ja) * | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
| US11396534B2 (en) | 2016-09-23 | 2022-07-26 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素类似物 |
| WO2018174668A2 (ko) | 2017-03-23 | 2018-09-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| WO2019066603A1 (ko) * | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
| WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| JP2021530533A (ja) | 2018-07-19 | 2021-11-11 | ディーアンドディー ファーマテック インコーポレイテッド | ポリペプチドを含む医薬組成物 |
| US11929171B2 (en) | 2018-10-18 | 2024-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020128967A2 (en) * | 2018-12-19 | 2020-06-25 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| WO2020167010A1 (ko) * | 2019-02-15 | 2020-08-20 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| KR102094103B1 (ko) * | 2019-05-08 | 2020-03-27 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 당뇨병 예방 또는 치료용 약학 조성물 |
| CN111944055B (zh) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| WO2022104394A1 (en) * | 2020-11-16 | 2022-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for diagnostic assessment and treatment of insulin resistance and hyperglycemia |
| CN121064327A (zh) * | 2024-06-03 | 2025-12-05 | 信达生物制药(苏州)有限公司 | Gipr、glp1r和/或gcgr的调节剂及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1999044630A1 (en) | 1998-03-06 | 1999-09-10 | Chugai Seiyaku Kabushiki Kaisha | Protein-free preparations |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| JP2007531513A (ja) * | 2003-11-13 | 2007-11-08 | ハンミ ファーム．インダストリー カンパニー リミテッド | 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法 |
| US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体 |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| EP1853627A2 (en) | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| BRPI0712383A2 (pt) | 2006-06-07 | 2012-07-10 | Human Genome Sciences Inc | proteìnas de fusão da albumina |
| GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| US20100196405A1 (en) | 2007-07-10 | 2010-08-05 | Kingman Ng | GLP-1 Fc FUSION PROTEIN FORMULATION |
| EP2187910A2 (en) | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
| AU2009292643B2 (en) | 2008-09-19 | 2016-02-18 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| EP2344200A2 (en) | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| AU2009327418A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010108154A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| EP2408800B1 (en) * | 2009-03-20 | 2016-05-25 | Hanmi Science Co., Ltd. | Method for preparing a site-specific conjugate of a physiologically active polypeptide |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| US20120294855A1 (en) | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| WO2011075393A2 (en) * | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR079345A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| US20130143798A1 (en) | 2010-03-26 | 2013-06-06 | Novo Nordisk A/S | Novel glucagon analogues |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN101974077A (zh) | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| KR101767570B1 (ko) * | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
| CN102010473A (zh) | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| JP6118500B2 (ja) | 2011-02-28 | 2017-04-19 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ | フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法 |
| KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
| HRP20181591T1 (hr) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže |
| AU2012270366C1 (en) | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| JP2015520128A (ja) | 2012-04-19 | 2015-07-16 | オプコ バイオロジクス リミテッド | 長時間作用性オキシントモジュリン変異体とその作製方法 |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| NZ739063A (en) | 2012-11-06 | 2019-11-29 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
-
2012
- 2012-11-06 KR KR1020120124724A patent/KR101993393B1/ko active Active
-
2013
- 2013-06-11 UA UAA201504676A patent/UA117570C2/uk unknown
- 2013-11-06 NZ NZ738835A patent/NZ738835A/en unknown
- 2013-11-06 SG SG11201503420QA patent/SG11201503420QA/en unknown
- 2013-11-06 SG SG10201703732VA patent/SG10201703732VA/en unknown
- 2013-11-06 SG SG10202110636WA patent/SG10202110636WA/en unknown
- 2013-11-06 JP JP2015540614A patent/JP6363613B2/ja active Active
- 2013-11-06 TW TW109122403A patent/TWI754980B/zh active
- 2013-11-06 BR BR122021003984-4A patent/BR122021003984B1/pt active IP Right Grant
- 2013-11-06 AU AU2013342324A patent/AU2013342324B2/en active Active
- 2013-11-06 TW TW107133431A patent/TWI741218B/zh active
- 2013-11-06 HU HUE13853226A patent/HUE049240T2/hu unknown
- 2013-11-06 UA UAA201802409A patent/UA130270C2/uk unknown
- 2013-11-06 BR BR112015010203-4A patent/BR112015010203B1/pt active IP Right Grant
- 2013-11-06 CN CN201380069535.8A patent/CN104918632B/zh active Active
- 2013-11-06 WO PCT/KR2013/009990 patent/WO2014073845A1/en not_active Ceased
- 2013-11-06 US US14/440,653 patent/US20150299282A1/en not_active Abandoned
- 2013-11-06 EP EP13853226.2A patent/EP2916860B1/en active Active
- 2013-11-06 AR ARP130104070A patent/AR093386A1/es not_active Application Discontinuation
- 2013-11-06 TW TW110124452A patent/TWI755341B/zh active
- 2013-11-06 MX MX2015005699A patent/MX360335B/es active IP Right Grant
- 2013-11-06 ES ES13853226T patent/ES2802099T3/es active Active
- 2013-11-06 EA EA201892383A patent/EA037956B1/ru unknown
- 2013-11-06 HR HRP20200925TT patent/HRP20200925T1/hr unknown
- 2013-11-06 LT LTEP13853226.2T patent/LT2916860T/lt unknown
- 2013-11-06 PT PT138532262T patent/PT2916860T/pt unknown
- 2013-11-06 DK DK13853226.2T patent/DK2916860T3/da active
- 2013-11-06 MX MX2018012968A patent/MX378848B/es unknown
- 2013-11-06 NZ NZ708105A patent/NZ708105A/en unknown
- 2013-11-06 PL PL13853226T patent/PL2916860T3/pl unknown
- 2013-11-06 TW TW102140248A patent/TWI645856B/zh active
- 2013-11-06 CA CA2890329A patent/CA2890329C/en active Active
- 2013-11-06 PE PE2015000594A patent/PE20151420A1/es not_active Application Discontinuation
- 2013-11-06 MY MYPI2015001149A patent/MY173828A/en unknown
- 2013-11-06 EA EA201590759A patent/EA031928B1/ru not_active IP Right Cessation
- 2013-11-06 EP EP20151111.0A patent/EP3679944B1/en active Active
- 2013-11-06 BR BR122019024272-0A patent/BR122019024272B1/pt active IP Right Grant
-
2015
- 2015-05-04 IL IL238631A patent/IL238631B/en active IP Right Grant
- 2015-05-06 CL CL2015001207A patent/CL2015001207A1/es unknown
- 2015-05-06 PH PH12015501009A patent/PH12015501009B1/en unknown
- 2015-06-04 ZA ZA2015/03999A patent/ZA201503999B/en unknown
-
2018
- 2018-01-08 AU AU2018200138A patent/AU2018200138B2/en active Active
- 2018-04-23 US US15/960,205 patent/US10550168B2/en active Active
- 2018-06-28 JP JP2018123263A patent/JP6666959B2/ja active Active
- 2018-07-03 PH PH12018501424A patent/PH12018501424B1/en unknown
-
2019
- 2019-12-04 AU AU2019275590A patent/AU2019275590B2/en active Active
-
2020
- 2020-02-21 JP JP2020028080A patent/JP7050834B2/ja active Active
- 2020-03-15 IL IL273305A patent/IL273305B/en unknown
-
2022
- 2022-02-04 JP JP2022016603A patent/JP7341263B2/ja active Active
- 2022-08-23 AR ARP220102265A patent/AR126851A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536943A5 (enExample) | ||
| RU2015104492A (ru) | Композиция для лечения гиперлипидемии, содержащая производное оксинтомодулина | |
| JP2015524427A5 (enExample) | ||
| HRP20200925T1 (hr) | Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina | |
| Ding et al. | Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications | |
| Getts et al. | Harnessing nanoparticles for immune modulation | |
| Mansour et al. | Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects | |
| JP2017529354A5 (enExample) | ||
| Hayder et al. | Phosphorus-based dendrimer ABP treats neuroinflammation by promoting IL-10-producing CD4+ T cells | |
| Petersen et al. | Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen | |
| Scott et al. | Overcoming immune dysregulation with immunoengineered nanobiomaterials | |
| JP2016512248A5 (enExample) | ||
| JP2015510880A5 (enExample) | ||
| NZ628828A (en) | Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease | |
| PE20181079A1 (es) | Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada | |
| JP2013519636A5 (enExample) | ||
| CN114901681A (zh) | 胰岛素衍生物 | |
| BR112013025221A8 (pt) | retenção de moléculas de ligação a antígeno em plasma sanguíneo e método para modificação de imunogenicidade | |
| JP2010500399A5 (enExample) | ||
| JP2018500394A5 (enExample) | ||
| JP2009520758A5 (enExample) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| JP2013503165A5 (enExample) | ||
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств |